Metastatisk Kastrationsresistent Prostatacancer: BEHANDLINGSMULIGHEDER TIL MCRPC-PATIENTER MED BRCA2 MUTATION

Abid Sayed, Mohammad Muddser Butt & Rasmus Nygaard Ibsen

Studenteropgave: Fagmodulprojekt

Abstrakt

Diseases come in many forms, from a mild cold to something as deadly as cancer. The deadliness derives from the cancer being able to spread through the bloodstream and lymph-system, and the persistence against treatment in cancer cells. The most common types of cancer that appear, usually consists of cancer in breast, bladder, colon, lung and prostate.
Usually cancer will be present in people of old age, and of much less severity in affecting the life of the patient. But in some cases, the cancer is malicious enough to resist many types of treatments, whilst also spreading rapidly. In these patients, genes typically play a vital role, as many sufferers of breast cancer and prostate cancer, have a mutation on chromosome 17 (BRCA1) or chromosome 13 (BRCA2), or both.
In this 5th semester project, we will focus on metastatic castration resistant prostate cancer (mCRPC), and the different lines of treatment for patients who also have a BRCA2 mutation.
In order to achieve this, we have analyzed three different studies written by Mateo et al., Kaufman et al. and Cheng et al. These studies focus on the use of inhibitors of Poly (ADP-ribose) polymerase protein (PARP), with the commercial name Olaparib, and the use of carboplatin for treatment of BRCA2 mutated mCRPC patients. Based on what the studies found, the PARP inhibitor, as tested Mateo et al. showed to have the most favorable effect in treating the BRCA2-mutated mCRPC, and had a higher success rate in a bigger group of patients.
Further research still needs to be conducted, as the true potential of either PARP inhibitors or treatment with platin is still to be determined.

UddannelserAlmen Biologi, (Bachelor/kandidatuddannelse) BachelorMolekylærbiologi, (Bachelor/kandidatuddannelse) Bachelor
SprogDansk
Udgivelsesdato19 dec. 2016
Antal sider52
VejlederePeter Michael Vestlev